A concerning trend has been noted from abortion advocates and their media allies in the face of any perceived threat to “abortion access.” As abortion limitations were implemented in many states in the wake of the Supreme Court’s Dobbs decision overturning Roe v Wade in 2022, medication abortion utilizing the FDA approved regimen of mifepristone and misoprostol was increasingly promoted, often in violation of state laws, and was estimated to induce nearly two-thirds of abortions in the U.S by 2023.[1]
Following the Food and Drug Administration’s 2023 decision to remove mifepristone’s in-person dispensing requirement, allowing these drugs to be prescribed by telemedicine or on-line and delivered via mail-order pharmacies,[2] use of these drugs has increased still further.[3] We and many others have expressed concern that medically unsupervised provision of these drugs without standard pre-abortion testing, or in-person informed consent counseling, jeopardizes the health and lives of women self-managing their abortions in this way.[4]
Read Full Article: https://www.lifenews.com/2026/05/22/abortion-industrys-dangerous-plan-will-kill-and-injure-more-women/
